KIT genetic alterations in anorectal melanomas

Background Mucosal melanomas (MM) represent a heterogeneous tumour population that exhibits site-specific molecular profiles. Aims In a multicentre retrospective study, we investigated KIT aberrations in primary anorectal (AR) melanomas compared with melanoma metastatic to the gastrointestinal (GI) tract. Methods Primary AR MM (n=31) and GI metastatic melanoma (n=27) were studied for KIT mutations on exons 11, 13, 17 and 18 by high-resolution melting analysis, direct sequencing and c-KIT expression by immunohistochemistry. Selected cases were also investigated for increased KIT gene copy number by fluorescent in situ hybridisation. Results Functional KIT mutations were demonstrated in 11/31 (35.5%) of AR melanomas and in 1/26 (3.8%) of GI melanoma metastases (p=0.004). A significant difference emerged between primary and metastatic MM with regards to KIT-positive immunostaining (p=0.002). Immunohistochemical c-KIT protein overexpression did not correlate with KIT mutational status. Increased KIT copy number was demonstrated in 5/20 AR primary cases. Conclusions The rate of functional mutations in KIT is significantly higher in AR MM than in GI metastatic melanoma. KIT protein overexpression does not correlate with KIT mutations and cannot be used for screening purposes. Recognising the molecular heterogeneity of MM helps to identify patients who require a different therapeutic approach.

[1]  Lu Jin,et al.  Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants , 2014, Cancer science.

[2]  A. D. Van den Abbeele,et al.  Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Carvajal.  Another option in our KIT of effective therapies for advanced melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  R. Dummer,et al.  Sinonasal, genital and acrolentiginous melanomas show distinct characteristics of KIT expression and mutations. , 2012, European journal of cancer.

[5]  Ye Xu,et al.  c-kit gene mutation and CD117 expression in human anorectal melanomas. , 2012, Human pathology.

[6]  A. Seth,et al.  KIT Gene Mutations and Patterns of Protein Expression in Mucosal and Acral Melanoma , 2012, Journal of cutaneous medicine and surgery.

[7]  Kristen Decarlo,et al.  Lack of Correlation Between Immunohistochemical Expression of CKIT and KIT Mutations in Atypical Acral Nevi , 2012, The American Journal of dermatopathology.

[8]  S. O’Day,et al.  Sunitinib Therapy for Melanoma Patients with KIT Mutations , 2012, Clinical Cancer Research.

[9]  E. Imyanitov,et al.  KIT mutations in Russian patients with mucosal melanoma , 2011, Melanoma research.

[10]  G. Schwartz,et al.  Treatment implications of the emerging molecular classification system for melanoma. , 2011, The Lancet. Oncology.

[11]  K. Flaherty,et al.  Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  L. Kanter‐Lewensohn,et al.  KIT Pathway Alterations in Mucosal Melanomas of the Vulva and Other Sites , 2011, Clinical Cancer Research.

[13]  C. Antonescu,et al.  KIT as a therapeutic target in metastatic melanoma. , 2011, JAMA.

[14]  E. J. Lee,et al.  KIT amplification and gene mutations in acral/mucosal melanoma in Korea , 2011, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[15]  R. Langer,et al.  Genetic aberrations in primary esophageal melanomas: molecular analysis of c-KIT, PDGFR, KRAS, NRAS and BRAF in a series of 10 cases , 2011, Modern Pathology.

[16]  R. Scolyer,et al.  Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care , 2011, Molecular oncology.

[17]  K. Flaherty,et al.  Large-Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma , 2011, Clinical Cancer Research.

[18]  A. Dobrovic,et al.  Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT , 2010, British Journal of Cancer.

[19]  R. Gutzmer,et al.  Anal Mucosal Melanoma with KIT-Activating Mutation and Response to Imatinib Therapy – Case Report and Review of the Literature , 2009, Dermatology.

[20]  S. Woodman,et al.  Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type , 2009, Modern Pathology.

[21]  G. Mills,et al.  Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates , 2009, Molecular Cancer Therapeutics.

[22]  M. Lens,et al.  Melanoma of the small intestine. , 2009, The Lancet. Oncology.

[23]  T. Saida,et al.  Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas , 2009, International journal of cancer.

[24]  R. Gutzmer,et al.  Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas , 2008, British Journal of Cancer.

[25]  Susan Muller,et al.  KIT Gene Mutations and Copy Number in Melanoma Subtypes , 2008, Clinical Cancer Research.

[26]  M. Ross,et al.  Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib , 2008, Nature Clinical Practice Oncology.

[27]  B. Bastian,et al.  Dose‐dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation , 2008, Pigment cell & melanoma research.

[28]  K. Flaherty,et al.  Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression. , 2008, Cancer research.

[29]  H. Nagatsuka,et al.  C-kit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma , 2008, Virchows Archiv.

[30]  A. D. Van den Abbeele,et al.  Major response to imatinib mesylate in KIT-mutated melanoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  H. Markogiannakis,et al.  Malignant gastrointestinal melanomas of unknown origin: should it be considered primary? , 2007, World journal of gastroenterology.

[32]  Narasimhan P. Agaram,et al.  L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition , 2007, International journal of cancer.

[33]  J. Messina,et al.  Primary mucosal melanoma. , 2007, Journal of the American Academy of Dermatology.

[34]  D. Pinkel,et al.  Somatic activation of KIT in distinct subtypes of melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  J. Lutzky,et al.  An immunohistochemical evaluation of c-kit (CD-117) expression in malignant melanoma, and results of imatinib mesylate (Gleevec) therapy in three patients , 2005, Melanoma research.

[36]  F. Mascarelli,et al.  Roles of Stem Cell Factor/c-Kit and Effects of Glivec®/STI571 in Human Uveal Melanoma Cell Tumorigenesis* , 2004, Journal of Biological Chemistry.

[37]  L. Karnell,et al.  The National Cancer Data Base report on cutaneous and noncutaneous melanoma , 1998, Cancer.

[38]  D. Coit,et al.  Melanoma metastatic to stomach, small bowel, or colon. , 1991, American journal of surgery.

[39]  G. Hutchins,et al.  Patterned distribution of metastases from malignant melanoma in humans. , 1983, Cancer research.

[40]  M. Didolkar,et al.  Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. , 1978, American journal of surgery.

[41]  Daan Brandenbarg.  The National. , 1892 .

[42]  B. Bastian,et al.  KIT as a therapeutic target in melanoma. , 2010, The Journal of investigative dermatology.

[43]  E. Furth,et al.  Melanoma in the gastrointestinal tract , 1999, American Journal of Gastroenterology.